Latest news
Watch: TVG CEO Dr Jeremy Salt on company’s next steps following Streptococcus suis vaccine success
The Vaccine Group’s recent success in trials for a Streptococcus suis vaccine follows that of its bovine respiratory syncytial virus vaccine candidates. Jeremy discusses their significance and the Company’s next steps.
Read moreStrong results for TVG vaccine against zoonotic pig disease Streptococcus suis
Challenge trials showed TVG vaccine candidate follows outstanding success in bovine respiratory syncytial virus and demonstrates the technology’s efficacy against diseases in different animals and against different pathogens.
Read moreGraphEnergyTech joins prestigious Japanese accelerator programme
GraphEnergyTech has opportunity to become a player in Japan’s advanced perovskite solar cell ecosystem after being selected for Japan’s KGAP+ accelerator programme. The Company has also launched a funding round.
Read moreOur portfolio
Our portfolio companies are involved in developing a wide range of technologies based on cutting-edge intellectual property to meet the needs and demands of the world.
See all companiesDekiln
Dekiln, formerly known as DeakinBio, has developed BioSintering®, a technology combining waste materials such as gypsum powder with bio-based active ingredients to produce a revolutionary, low-carbon alternative to traditional ceramic tiles.
Learn more